Trial · NCT04777331
Adverse events186
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 186
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | DBT Period: Placebo | 15 | 290 | 16 |
| other | Constipation | Gastrointestinal disorders | DBT Period: Prasinezumab | 19 | 292 | 26 |
| other | Diarrhoea | Gastrointestinal disorders | DBT Period: Placebo | 13 | 290 | 17 |
| other | Diarrhoea | Gastrointestinal disorders | DBT Period: Prasinezumab | 15 | 292 | 21 |
| other | Fatigue | General disorders | DBT Period: Placebo | 11 | 290 | 11 |
| other | Fatigue | General disorders | DBT Period: Prasinezumab | 21 | 292 | 23 |
| other | COVID-19 | Infections and infestations | DBT Period: Placebo | 68 | 290 | 77 |
| other | COVID-19 | Infections and infestations | DBT Period: Prasinezumab | 84 | 292 | 96 |
| other | Influenza | Infections and infestations | DBT Period: Placebo | 16 | 290 | 16 |
| other | Influenza | Infections and infestations | DBT Period: Prasinezumab | 21 | 292 | 23 |
| other | Nasopharyngitis | Infections and infestations | DBT Period: Placebo | 31 | 290 | 46 |
| other | Nasopharyngitis | Infections and infestations | DBT Period: Prasinezumab | 36 | 292 | 48 |
| other | Upper respiratory tract infection | Infections and infestations | DBT Period: Placebo | 19 | 290 | 21 |
| other | Upper respiratory tract infection | Infections and infestations | DBT Period: Prasinezumab | 21 | 292 | 30 |
| other | Urinary tract infection | Infections and infestations | DBT Period: Placebo | 32 | 290 | 44 |
| other | Urinary tract infection | Infections and infestations | DBT Period: Prasinezumab | 24 | 292 | 36 |
| other | Fall | Injury, poisoning and procedural complications | DBT Period: Placebo | 30 | 290 | 60 |
| other | Fall | Injury, poisoning and procedural complications | DBT Period: Prasinezumab | 34 | 292 | 58 |
| other | Infusion related reaction | Injury, poisoning and procedural complications | DBT Period: Placebo | 36 | 290 | 87 |
| other | Infusion related reaction | Injury, poisoning and procedural complications | DBT Period: Prasinezumab | 31 | 292 | 55 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04777331/events